1 EPI Routine vaccines Pentavalent, Hexavalent and traditional EPI vaccines Industry Consultation UNICEF Supply Division January 2012
2 Presentation Overview Pentavalent vaccine evolution where are we now? Moving forward 2013 and beyond Other traditional EPI vaccines: DTP, DT, HepB, BCG
3 Vaccine Security: Ensuring the uninterrupted, sustainable supply of affordable vaccines of assured quality The concept of Vaccine Security continues to guide our approach to secure and supply routine vaccine for countries EPI programmes. For the future we will focus on: Balancing supply and demand to ensure supply security Focusing on both price and cost of products, ensuring that more elements of affordability are incorporated Enabling the future EPI schedule
4 A changing EPI schedule catalysed by GAVI support for introduction of HepB and Hib containing vaccines All DTP-containing vaccines procured through UNICEF (GAVI and non-gavi eligible country demand) The transition from DTP has been challenging to forecast accurately and is now resulting in stock-outs and a global shortage of pre-qualified DTP pre-qualified vaccine.
5 Pentavalent introduction via GAVI support and UNICEF procurement (as of end 2011) In out of 67 GAVI eligible countries will have introduced pentavalent vaccines, the majority with procurement through UNICEF.
6 Pentavalent vaccine demand and pricing Steep demand growth in the past years, expecting growth to continue but at a slower pace in the next 4 year period as programmes reach full implementation Declining prices due to new supplier base and availability of multidose vials
7 Procurement objectives: Procurement objectives focused on: - enabling accelerated introduction and use of new vaccines - making available products that met countries needs and preferences - creating a market that would be sustainable with affordable pricing In 2006 the GAVI Board approved 3 specific procurement objectives that guided UNICEF procurement: 1. A healthy market: ensuring the sustainable quantity of supply through a diverse supplier base 2. Select products and presentations that best meet the need of client countries 3. Achieving a long term affordable price that countries can eventually finance in a sustainable manner
8 Assessment of pentavalent vaccine procurement objectives for the procurement round Objective 1. A healthy market: ensuring the sustainable quantity of supply through a diverse supplier base 2. Select products and presentations that best meet the need of client countries 3. Achieving a long term affordable price that countries can eventually finance in a sustainable manner Assessment ( ) 1. Growth in supplier base, but still volatile; 2 new suppliers, 2 de-listed. Today sufficient pentavalent to supply all countries, but requiring close management 2. Introduction of 2 new presentations, enabling a shift in demand from small vials towards 10 dose vials 3. Starting to see reduction in WAP due to new supplier base and multidose vials.
9 The initial offer and award volumes for for Pentavalent vaccines With increased demand quantities and increased competition, we expected price to decrease Even with an expanded supplier base, the WAP is only just below $3.00. However, the newer lower priced products give a positive indication of lower prices ahead
10 Current procured volumes and WAP development for for Pentavalent vaccines that already started to materialize with the additional awards made during the period, and we are now looking at a WAP for 2012 of $2.33 per dose across all presentations. Note: the offered quantity and forecasts reflect the 2009 situation
11 Contracted Pentavalent vaccine prices With increased demand quantities and increased competition, we expected price to decrease Need continued focus on affordable prices from manufacturers
12 Pentavalent : Increasing demand and significant changes in the supplier base Supply complexity: Delays in pre-qualification timelines, supplier de-listings, recall, availability delays, engaging alternative supply. We appreciate manufacturers' flexibility and responsiveness, avoiding prolonged disruptions to immunization programmes. Demand changes: Supporting introduction of 10 dose vials (in 19 countries so far) Uncertainty during this period around the introduction plans of India and Nigeria
13 New presentations meeting country demand 19 countries introduced 10 dose vials in 2011.
14 Moving Forward: In November 2011 the GAVI Board approved the GAVI Supply and Procurement Strategy that will guide GAVI supported procurement through UNICEF GAVI Vaccine Supply and Procurement Objectives 1. Balance of supply/demand Ensure sufficient availability to at least meet total GAVI demand Provide consistent uninterrupted supply to GAVI countries. 2. Cost of vaccine to GAVI and countries Minimize cost per course Minimize cost implications 3. Appropriate and innovative vaccines Procurement of appropriate, quality vaccines to meet GAVI country needs Foster an environment for innovative vaccines Information: Communicate timely, transparent and accurate market information
15 Moving forward: What market are we entering in 2013? Demand: Growing at a slower pace, and with higher visibility than in the past, as the majority of countries already have introduced. Some fragmentation of funding streams. GAVI financing still supports the majority of the demand. Co-financed doses are increasing towards 1/5 of the demand in a couple of years Graduated countries represent a small portion of expected demand for Remaining demand uncertainties in GAVI countries: India scale-up plan, timing of co-financed demand, graduated countries procurement strategy, and impact of longer term more combination vaccines (hexa) on penta demand. Supply: Market has been growing, but is still unstable Expected to stabilize with increased capacity and more presentations over the period Positive signals on more affordable pricing from the growing supplier base
16 Total demand projections for pentavalent vaccine through UNICEF Forecasts will be refined prior to tender issuance Assumptions: India will introduce and use pentavelent in 8 states throughout the period, but this may increase. India demand will be specified in the tender and we will request specific delivery terms for India. GAVI Graduated countries procure through UNICEF
17 GAVI financed & Co-financed demand projections through UNICEF Tender quantities. Co-financing increases from current around10% towards 25% of the GAVI financed demand in India assumption 8 states. Includes forecasts from GAVI graduated countries in 2016
18 Pentavalent vaccine Demand scenario by country product preference 10 dose vials 2 dose lyo vials 1 dose vials Based on the currently expressed country preference may change over time Does not include any future hexavalent that could impact demand / preference Reliability of supply higher with lyophilized production? Requesting feedback from manufacturers to help inform countries future demand preferences.
19 The other future.. Initial IPV containing vaccine scenarios Standalone IPV anticipated to be the preferred product during the eradication and topv-bopv switch phases The following IPV scenarios for potential use of IPV in polio eradication, have been created based on guidance input from programme partners. They represent a combination of routine and campaign activities, with 1 or 2 dose scenarios for the eradication phase, and 3 early scenarios for future demand of IPV in combinations. Low cost hexavalent anticipated to be the preferred product in the 'post-opv' period,
20 A programmatic demand scenario for IPV Consolidated demand plus India. Up to 58 million full dose equivalents w/india. ID quantities are shown as full dose equivalents and based on 2 dose schedule
21 An exploratory hexavalent scenario: Low cost IM hexavalent with full dose IPV for routine introduction An affordable hexavalent would need to be available before universal introduction and use of IPV. This is an unconstrained scenario there would need be a transition from the ID stand alone product to Hexa, this would not happen over night in 2017
22 Strategic tender issues - Innovations in procurement Objective for the Pentavalent tender: Securing supply, bringing stability to the market while achieving affordable vaccine prices and enable future development of the EPI schedule, in alignment with the GAVI SPS objectives. Opportunity to provide innovative proposal features to help us achieve exceptional results. We invite all interested to provide proposals. All valid offers are considered and help inform the award strategy, including on how much demand to keep open for later awards. We will be working with GAVI partners to explore various possibilities to achieve the objectives.
23 Innovative elements - products, offers and awards We are requesting feedback on the approach to make sure we ask in a way that will solicit the best offers : Meeting the call for lower, affordable prices Increased focus on products that enable in country logistics and distribution: low shipping volume and cold chain requirements, primary container volumes and characteristics, different presentations that can meet countries needs etc. Include offers and information on potential alternatives such as lyophilized/liquid, DTaP, and alternatives. We will also request that proposals inform of / or offer future hexavalent vaccines, focusing on the plans and milestones for decision making.
24 Period covered by the tender: years to consider the supply pipeline, opportunity to secure long term attractive offers In 2016, inclusion of demand from graduated GAVI countries procuring through UNICEF. Include scenarios requesting hexavalent product offers for the tender period and indications for the following 2 years ( ). Demand will depend on polio programme progress, country IPV decision making, and affordable supply availability.
25 Tender timeline for pentavalent tender onwards January 2012: Pre-tender meeting for all relevant vaccines with manufacturers and partners February: Feedback on tender strategies End March: Issue tender documents with 6-8 week response time May-August: Review offers, clarifications with manufacturers, consultations, internal review processes September: Awards to manufacturers Jan 2013 Start of supply from new contracts
26 Vaccine Security for traditional EPI routine vaccines HepB, BCG, DTP, TT, Td, DT will tendered for together covering the period
27 DTP an overview of procurement, awards and forecast Declining demand due to transition to DTP combination vaccines The challenge is to meet demand changes in a declining market trend. Vaccine shortages in 2011/2012.
28 DTP forecasted demand through UNICEF Forecasts in doses per year DTP-10 12,000,000 6,000,000 6,000,000 6,000, DTP , , , ,000 Objective will be to secure sustained supply at affordable prices from more than one supplier to ensure flexibility and supply security forecasts is included to show the continued expected demand level. Tender will also include DT demand:
29 HepB - an overview of procurement, awards and forecasts Declining demand due to transition to DTP combination vaccines GAVI no longer funds stand alone HepB vaccine Still demand from some countries that use HepB birth dose Expecting HepB market to stabilize at this lower level.
30 HepB forecasted demand through UNICEF Forecasts in doses per year Objective will be to secure sustained supply at affordable prices from multiple suppliers.
31 BCG - an overview of procurement, awards and forecast Stable demand levels for BCG vaccine this is expected to continue Complex and varying funding sources backing the demand at individual country level stable funding at the aggregate level
32 BCG forecasted quantities though UNICEF Forecasts in doses per year BCG ,000, ,000, ,000, ,000,000 Tender objective is to ensure continued Vaccine Security for a basic childhood vaccine Focus on achieving affordability and multiple suppliers for continued future supply of this vaccine
33 Tender timeline for traditional EPI vaccines onwards January 2012: Pre-tender meeting for all relevant vaccines with manufacturers and partners February: Tender issuance Mid April : Tender closure April - June: Review offers, clarifications with manufacturers, consultations, internal review processes June: Awards to manufacturers Jan 2013 Start of supply from new contracts
UNICEF Supply Division Vaccine Procurement Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow Veyrier-du-Lac - France 19-21 January 2015 UNICEF Strategic Plan 2014-2017-
UNICEF Vaccine Procurement Overview: priorities, status and way forward Vaccine Procurement: Overview UNICEF has a key role in vaccine procurement and procuring immunization supplies on behalf of around
Update on Rotavirus Vaccine Industry Consultation Meeting UNICEF Supply Division 25-26 January 2012 Overview of presentation Update on country demand for Rotavirus Vaccine Procurement activities and results
An introduction to the switch from trivalent to bivalent oral polio vaccines February 2015 1 Contents 1. Rationale for OPV withdrawal 2. Timelines for switching from topv to bopv 3. Programmatic implications
Central African Republic: WHO and UNICEF estimates of immunization coverage: 2015 revision July 6, 2016; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division February 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Update February 2013 A more recent note covering
Saint Lucia: WHO and UNICEF estimates of immunization coverage: 2014 revision July 9, 2015; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2016 data
The Market Shaping Goal Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries. Gavi Supply and Procurement Roadmap Streptococcus
BCG Vaccine: Current Supply & Demand Outlook UNICEF Supply Division August 2014 0 Bacillus Calmette-Guérin (BCG) Vaccine Supply & Demand Update August 2014 This update provides new information on BCG supply
Joint appraisal report Country Sri Lanka Reporting period October 2014 May 2015 cmyp period 2012-2016 Fiscal period Month - Month 1. EXECUTIVE SUMMARY 1.1. Gavi grant portfolio overview Sri Lanka has received
Malaysia: WHO and UNICEF estimates of immunization coverage: 2015 revision July 6, 2016; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2017 data as
Introducing Hepatitis B Vaccine into National Immunization Programmes José Bengoa Training Course in Reproductive Health Research WHO 2007 New Vaccine Introduction Assess disease burden Assess effectiveness
China: WHO and UNICEF estimates of immunization coverage: 2015 revision July 6, 2016; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2017 data as of
VIETNAM SUPPORT for INACTIVATED POLIO VACCINE (IPV) This Decision Letter sets out the Programme Terms of a Programme.. Country: Vietnam 2. Grant Number: 58-VNM-25c-X /5-VNM-08h-Y 3. Date of Decision Letter:
Procurement of Pneumococcal Vaccines under the Advance Market Commitment Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen From 2009 and 2010, 11 GAVI-supported countries are
Expanded Programme on Immunization Expanded Programme on Immunization has been delivered the immunization services to the targeted children of under one year old child and pregnant women. Currently total
The GAVI Alliance The GAVI Alliance White paper White paper Market shaping: strategic considerations for a healthy vaccine marketplace Market shaping: strategic considerations for a healthy vaccine marketplace
Aurelie Baumel/MSF Pneumococcal Conjugate Vaccines (PCV) WHO recommendations & general information Every year, 2.58 million episodes of severe pneumonia caused by Streptococcus pneumoniae occur globally
Costa Rica: WHO and UNICEF estimates of immunization coverage: 2014 revision July 9, 2015; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2016 data
FACT FILE: Polio Eradication and Endgame Strategic Plan 2013 2018 Global polio cases are at an all-time low. In 2012, the world saw the fewest polio cases in the fewest countries ever. India, long regarded
Overview of WHO revised vaccine prequalification procedure Carmen Rodriguez WHO/IVB/QSS Vaccine Industry Consultation meeting 25-26 January 2012 UNICEF SD Copenhagen Purpose of WHO vaccines prequalification
GAVI FULL COUNTRY EVALUATION 2013 PROCESS EVALUATION OF PNEUMOCOCCAL VACCINE INTRODUCTION ALLIANCE RESPONSE JULY 2014 The GAVI Alliance is a learning organisation; we take the need for independent evaluation
Optimizing vaccine supply chains More and more vaccines are becoming available Since immunization programs were launched worldwide in the mid-1970s, most countries have been using the same standard package
Breakeven Analysis for Various Human Papillomavirus Vaccine Presentations in Vietnam and Uganda August 2010 Batiment Avant Centre 13 Chemin du Levant 01210 Ferney Voltaire France Phone: 33.450.28.00.49
Practical Checklist to Use PEI to Strengthen the Routine Immunization Program - Robert Steinglass - Rebecca Fields Presented at the Technical Consultation on the Global Eradication of Poliomyelitis. WHO,
NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL Polio Campaigns With fewer than 600 days remaining to the Millennium Development Goal (MDG) deadline, new strategies
United States of America: WHO and UNICEF estimates of immunization coverage: 2015 revision July 6, 2016; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July
Immunization in the Philippines: Current Trends and the Way Forward Maria Joyce U. Ducusin, MD, MPH Director III, Family Health Office Department of Health Philippines Country Background 2.3 Million estimated
Beyond the cold chain Meningitis A conjugate vaccine in a controlled temperature chain (CTC): Experience from Benin Olivier Ronveaux email@example.com GVRF Washington DC March, 2014 WHO recommended storage
Vaccination Puzzle: What would you give? Chris Shepherd RN BSN Work in a group of 3 4 Decisions: What vaccinations does this child need to get to be up to date? What vaccinations will be given today? When
Title: Determinants of full child immunization among 12-23 months old in Nigeria Long abstract Morbidity and mortality in children are mainly due to preventable diseases such as measles, poliomyelitis,
6 INTRODUCTION Immunization in India - Past, Present and Future Immunization is a proven tool for controlling and even eradicating disease. An immunization campaign carried out by the World Health Organization
Comoros: WHO and UNICEF estimates of immunization coverage: 2013 revision July 8, 2014; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2015 data as
Monitoring and Evaluation Framework and Strategy GAVI Alliance 2011-2015 NOTE TO READERS The 2011-2015 Monitoring and Evaluation Framework and Strategy will continue to be used through the end of 2016.
Children in Egypt 2014 A STATISTICAL DIGEST CHAPTER 4 IMMUNIZATION AND HEALTH Children in Egypt 2014 is a statistical digest produced by UNICEF Egypt to present updated and quality data on major dimensions
To GAVI Alliance s Draft Vaccine Supply and Procurement Strategy for the period 2011-2015 Section A: Overview 1. Purpose of this document 1.1 The purpose of this document is to provide background information
Gavi, the Vaccine Alliance: Supply and Procurement Strategy 2016-20 Executive Summary Four strategic goals guide the mission of Gavi, the Vaccine Alliance. Its fourth strategic goal (SG4) is to shape markets
Supply Annual Report 2015 feature Supply financing solutions for children Interventions to meet increased demand for affordable lifesaving supplies in a rapidly changing global context Cover photo Nepal:
Module 7 Expanded Programme of Immunization (EPI) (including Vitamin A, Tetanus Toxoid and Growth Monitoring) CONTENTS 7.1 What are the tools used for data collection?....................................2
Vaccine-Preventable Disease Control in the Western Pacific Region Mark Jacobs Director, Communicable Diseases Outline Regional goals Disease-specific updates Hepatitis B Measles Polio Rubella Tetanus Remaining
Options for the future of Meningococcal B Vaccine (MeNZB ) in the Childhood Immunisation Schedule Meningococcal Vaccine Strategy Team 1 Executive Summary While there is good evidence that MeNZB is effective,
Chapter 1. Executive Summary Background With 5.6 million people living with HIV/AIDS, South Africa is home to the world s largest population of people in need of treatment. In 2009, the president of South
Immunization Program: Planning and Forecasting Anne Schuchat, MD Director, NCIRD and RADM, US Public Health Service Centers for Disease Control and Prevention National Vaccine Advisory Committee June 10,
Summary report Meeting of the Regional Technical Advisory Group (RTAG) on immunization of the WHO Eastern Mediterranean Region Amman, Jordan, 21 November 2013 Introduction The annual Meeting of the Regional
The Gavi grant management change process Overall change process Frequently asked questions June 2015 1. How was it decided that grant management changes were needed? Over recent years, through a series
Children in Egypt 2015 A STATISTICAL DIGEST Chapter 4 Immunization and Health Children in Egypt 2015 Children in Egypt 2015 is a statistical digest produced by UNICEF Egypt to present updated and quality
Guidelines on Reporting and Renewals in 2016 for all types of support Document dated: May 2016 Purpose of the document: This document provides guidance on the reporting process and requirements for all
Policy Considerations for Introduction of Dengue Vaccine in Sri Lanka DVI ASIA-PACIFIC DENGUE PREVENTION BOARD April 20, 2011 Epidemiology Unit Ministry of Health Sri Lanka Dr Paba Palihawadana Chief Epidemiologist
Summary of GAVI Alliance Investments in Immunization Coverage Data Quality The GAVI Alliance strategy and business plan for 2013-2014 includes a range of activities related to the assessment and improvement
FAQ on Changes in the NC Immunization Program (NCIP) Information for Local Health Departments RECENT CHANGES IN THE NCIP 1. What changes have occurred in the state program that supplies vaccine to children
REVISED : OCTOBER 2010 This document was published by: The National Department of Health Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo Copies may be obtained from: The National Department
Emergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency Introduction The 2014 Ebola outbreak is the largest Ebola epidemic in history,
Securing Polio s Legacy Transition Planning March 2015 Frequently Asked Questions Context In May 2013, the 66 th World Health Assembly endorsed the Polio Eradication and Endgame Strategic Plan 2013-2018.
頴 眫 蘟 蘟 蘟 ή ή ήministry 虒 Rainy River District School Board of Education Follow-up Report to the Operational Review July 2010 TABLE OF CONTENTS 1. INTRODUCTION...1 2. STATUS AND IMPLEMENTATION UPDATE...3
Vaccine regional distribution center cost assessment December 2011 Batiment Avant Centre 13 Chemin du Levant 01210 Ferney Voltaire France Phone: 33.450.28.00.49 Fax: 33.450.28.04.07 www.path.org www.who.int
Table I. IAP Immunization Timetable 2016 I. IAP recommended vaccines for routine use Age (completed weeks/months/years) Vaccines Comments Birth 6 weeks BCG OPV 0 Hep-B 1 Administer these vaccines to all
The Cold Chain and Vaccine storage Cliona Kiersey Chief Pharmacist National Immunisation Office Objectives To explain the cold chain and vaccine delivery service including importance of using vaccine returns
Quick guide: Catch-up immunisation for Victoria For people with no documentation of previous vaccines Always use the current edition of the Australian Immunisation Handbook for complete advice Department
Polio and the Introduction of IPV Poliomyelitis (polio) is a highly infectious disease that is caused when a person is infected by the polio virus that invades the nervous system. Poliomyelitis can cause
Overview of UNICEF Supply Division Safe Injection Equipment Industry Consultation Meeting 21 st April, 2015 1 GLOBAL CONTEXT The child health agenda : MDGs (2015) 4,5 & 6 A Promised Renewed (2012- Ethiopia/India/USA/UNICEF).
Issues Management and Media Guide To support countries in preparing for unexpected situations with implications for public communications around the switch from trivalent OPV to bivalent OPV May 2015 Contents
1 of 5 7/30/2014 9:47 AM TITLE 77: PUBLIC HEALTH CHAPTER I: DEPARTMENT OF PUBLIC HEALTH SUBCHAPTER i: MATERNAL AND CHILD HEALTH PART 665 CHILD HEALTH EXAMINATION CODE SECTION 665.240 BASIC IMMUNIZATION
Risk Analysis and Risk Mitigation Plan/ Product and Process Design 30 June 2015 Jolanta Wozniak Quality Assurance Centre UNICEF SUPPLY DIVISION Strategy to mitigate risks related to supply of nutrition
Strategic Analysis of the South African Paediatric Vaccine Market Healthcare M1A7-52 Published: October 2007 1 Background to Study Slide 3 Research Aims and Objectives Slide 5 Scope of Research and Respondent
Immunization coverage: children Rationale Vaccination programs are one of the priority interventions in all countries. All children should have all vaccinations everywhere. More vaccines are added to the
OPTIMIZE Albania Report This report was commissioned by Optimize: Immunization Systems and Technologies for Tomorrow, a collaboration between the World Health Organization and PATH. The report was authored
Vaccine presentation for pneumococcal conjugate vaccines GAVI Vaccine Presentation and Packaging Advisory Group: Interim Report for the TPP Final draft: 10 th August 2007 198-pneumo-report-final-070810.doc
Operating Procedures of the PAHO Revolving Fund for the Purchase of Vaccines, Syringes, and Other Related Supplies May 2011 Operating Procedures of the Revolving Fund for the Purchase of Vaccines, Syringes,
Continuous Sales & Operations Planning Aamer Rehman VP, Manufacturing Solutions Las Vegas - Jan 27, 2012 Copyright 2012 Kinaxis Inc. All Rights Reserved. Prelude Volatility is a given in today s environment
c 30 WHO Vaccine Management Handbook Module VMH-E2-01.1 WHO/IVB/15.04 WHO/IVB/13.XX ORIGINAL: ENGLISH DISTRIBUTION: GENERAL HOW TO MONITOR TEMPERATURES IN THE VACCINE SUPPLY CHAIN July 2015 20 10-10 0-20
Chapter 17 1 A Model of Estimating the Direct Benefits of Implementing Electronic Data Exchange of EMRs and State Immunization Information Systems Michael L. Popovich, MSSE, CEO, Scientific Technologies
1. Introduction UNRWA is in the process of implementing a new Enterprise Resource Planning (ERP) system, to provide an integrated information system that will: fully support the growing needs of the Agency;
Ikram N gadi -containing Vaccines (, MR, MMR) WHO recommendations & general information -containing vaccines include combination vaccines for measles and rubella (MR) and for measles, mumps and rubella
The Advance Market Commitment Pilot for Pneumococcal Vaccines: Outcomes and Impact Evaluation The Boston Consulting Group December 10, 2015 Table of Contents Acronyms and Abbreviations... 2 1. Executive
Pertussis Vaccination Schedules Summary and recommendations Claire-Anne Siegrist Chair of the Pertussis Working Group SAGE Meeting 14-16 April 2015 FOR DECISION Review the evidence in support/against different
Public Private Partnerships 21st Century Development Models March 2013 Harnessing Innovation and Inclusiveness for Global Health Executive Summary Today s challenges and the post-2015 development goals
No Goal Indicator Operational definition Data source/ collection Baseline Target Milestones G 1.1 Achieve a world free of poliomyelitis Interrupt wild poliovirus transmission globally G1.2 Certification
DIPHTHERIA, TETANUS, PERTUSSIS (DTaP, DT, Td, Tdap) All students entering child care/preschool and kindergarten through 12 th grades must get vaccinated against diphtheria, tetanus, and pertussis. Routine
Lessons learned from catalyzing and sustaining access to Pediatric HIV treatments Dr. David Ripin IOM Workshop: Aug 1 2012, Washington DC In 2006, the pediatric ARV market was nascent with very few HIV+
IBM Sales and Distribution Chemicals and Petroleum White Paper Tapping the benefits of business analytics and optimization A rich source of intelligence for the chemicals and petroleum industries 2 Tapping
MEMO TO: FROM: RE: Prevention Partnership Providers and Local Public Health Units Tatia Hardy Vaccines for Children Coordinator New Hib Vaccine Available DATE: October 12, 2009 The Food and Drug Administration
Andrea Bruce/Noor Images WHO recommendations & general information Cholera is an acute diarrhoeal disease, caused primarily by the O1 and O139 toxigenic serogroups of the Vibrio cholerae bacterium. The
Version No.: 2.0 Page 1 / 8 DOCUMENT ADMINISTRATION VERSION NUMBER APPROVAL PROCESS 1.0 Approved by: The Alliance & Fund Boards 26 June 2008 DATE Effective from: 01 January 2009 Review: On yearly basis
First Steps for Newcomers to the San Francisco Bay Area Community Connection s First Steps information sheets answer frequently asked questions about various aspects of SF Bay Area living Bay Area School
msd medical stores department Operations and Sales Planning (O&SP) Process Document August 31, 2011 Table of Contents 1. Background... 3 1.1. Objectives... 3 1.2. Guiding Principles... 3 1.3. Leading Practice...
GAVI Alliance Annual Progress Report 2010 Submitted by The Government of Nigeria Reporting on year: 2010 Requesting for support year: 2012 Date of submission: 31.05.2011 15:35:38 Deadline for submission:
Immunization Supply Chain and Logistics: a neglected but essential system for national immunization programmes A Call- to- Action for national programmes and the global community by the WHO Immunization
National Childhood Immunisation Schedule and Late entrants Objectives To outline how new vaccines are added to the National Schedule the Primary Childhood Immunisation Schedule and recent changes the School